We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Dechra Pharmaceuticals Plc | LSE:DPH | London | Ordinary Share | GB0009633180 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3,866.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMDPH
RNS Number : 2365U
Dechra Pharmaceuticals PLC
20 October 2017
Date: 20 October 2017
Dechra(R) Pharmaceuticals PLC
Results of Annual General Meeting (AGM)
AGM Meeting Date: 1pm on 20 October 2017
Issued Share Capital at meeting date: 93,415,750
Number of shareholders in attendance: 12
All resolutions were passed on a show of hands.
Details of the proxy voting instructions lodged prior to the AGM are set out below:
Resolution (No. Total For Total Against Withheld as noted on proxy (1) (2) form) -------------------------------------- ------------------- ------------------ ---------- No. of % No. of % No. of votes of votes of votes vote vote -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 1: To receive the accounts, the Strategic Report, the Directors' Report and the Auditor's Report 69,787,352 94.83 3,801,367 5.17 176,986 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 2: To receive and approve the Directors' Remuneration Report 66,111,495 94.18 4,086,647 5.82 3,567,713 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 3: To receive and approve the Directors' Remuneration Policy 72,932,631 98.88 823,955 1.12 8,619 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 4: To declare a final dividend 73,764,546 100 0 0.00 659 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 5: To elect Richard Cotton 72,195,608 97.87 1,568,938 2.13 659 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 6: To elect Lawson Macartney 73,401,877 99.51 361,469 0.49 1,859 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 7: To re-elect Tony Rice 66,992,715 92.48 5,448,270 7.52 1,324,220 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 8: To re-elect Ian Page 72,285,663 98.00 1,478,883 2.00 659 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 9: To re-elect Anthony Griffin 72,279,341 97.99 1,485,205 2.01 659 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 10: To re-elect Julian Heslop 73,500,858 99.64 263,688 0.36 659 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 11: To re-elect Ishbel Macpherson 73,144,501 99.16 620,045 0.84 659 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 12: To reappoint PricewaterhouseCoopers as external auditor of the Company 73,756,778 99.99 7,318 0.01 1,109 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 13: To authorise the Audit Committee to determine the remuneration of the external auditor 73,763,069 100 1,027 0.00 1,109 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 14: To authorise the Directors to allot shares to specific limits 69,568,791 94.32 4,191,805 5.68 4,609 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 15: To disapply the pre-emption rights 72,858,327 98.78 903,219 1.22 3,659 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 16: To disapply additional pre-emption rights 67,395,228 91.37 6,366,318 8.63 3,659 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 17: To authorise the Company to purchase its own shares 72,978,224 99.07 685,466 0.93 101,515 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 18: To call general meetings (other than an AGM) on not less than 14 clear days' notice 71,828,591 97.38 1,935,505 2.62 1,109 -------------------------------------- ----------- ------ ---------- ------ ---------- Resolution 19: (a) To approve the rules of the LTIP 2017; and (b) To authorise the Directors to adopt further schemes based on the LTIP 2017 70,433,043 95.49 3,328,963 4.51 3,199 -------------------------------------- ----------- ------ ---------- ------ ----------
Notes
1. Includes discretionary votes.
2. A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "For" and "Against" a resolution.
3. Resolutions 1 to 14 and Resolution 19 were ordinary resolutions, requiring more than 50% of shareholder votes to be "for" the resolutions.
4. Resolutions 15 to 18 were special resolutions, requiring more than 75% of shareholder votes to be "for" the resolutions.
5. Votes tendered in respect of 73,765,205 shares representing 78.96% of the issued share capital.
In accordance with Listing Rule 9.6.2R, a copy of the resolutions passed as special business at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.
For further information
Melanie Hall, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: www.dechra.com.
Trademarks
Trademarks appear throughout this document in italics. Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGFMMZGFGDGNZM
(END) Dow Jones Newswires
October 20, 2017 09:35 ET (13:35 GMT)
1 Year Dechra Pharmaceuticals Chart |
1 Month Dechra Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions